Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase

Science

Volumn 318, Issue 5856, 2007, Pages 1637-1640

  Kolas, Nadine K ^a   Chapman, J Ross ^b   Nakada, Shinichiro ^a   Ylanko, Jarkko ^a,c   Chahwan, Richard ^b   Sweeney, Frédéric D ^a,c   Panier, Stephanie ^a   Mendez, Megan ^a   Wildenhain, Jan ^a   Thomson, Timothy M ^d   Pelletier, Laurence ^a,c   Jackson, Stephen P ^b   Durocher, Daniel ^a,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BINDING PROTEIN; BRCA1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; P53 BINDING PROTEIN 1; PROTEIN KINASE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE RNF8; UNCLASSIFIED DRUG;

DAMAGE; DNA; ENZYME ACTIVITY; LESION; PROTEIN;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONJUGATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BRCA1 PROTEIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS STRUCTURES; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

ATAXIA TELANGIECTASIA;

EID: 36749084931     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1150034     Document Type: Article

References (28)

1. J. Bartek, J. Lukas, Curr. Opin. Cell Biol. 19, 238 (2007).
2. R. S. Maser, K. J. Monsen, B. E. Nelms, J. H. Petrini, Mol. Cell. Biol. 17, 6087 (1997).
3. T. Stiff et al., Cancer Res. 64, 2390 (2004).
4. T. T. Paull et al., Curr. Biol. 10, 886 (2000).
5. A. Celeste et al., Nat. Cell Biol. 5, 675 (2003).
6. S. Bekker-Jensen et al., J. Cell Biol. 173, 195 (2006).
7. M. Stucki et al., Cell 123, 1213 (2005).
8. Z. Lou et al., Mol. Cell 21, 187 (2006).
9. M. S. Lee, R. A. Edwards, G. L. Thede, J. N. Glover, J. Biol. Chem. 280, 32053 (2005).
10. S. Bekker-Jensen, C. Lukas, F. Melander, J. Bartek, J. Lukas, J. Cell Biol. 170, 201 (2005).
11. G. S. Stewart, B. Wang, C. R. Bignell, A. M. Taylor, S. J. Elledge, Nature 421, 961 (2003).
12. M. Goldberg et al., Nature 421, 952 (2003).
13. J. Yan et al., Cancer Res. 67, 6647 (2007).
14. H. Kim, J. Chen, X. Yu, Science 316, 1202 (2007).
15. B. Sobhian et al., Science 316, 1198 (2007).
16. B. Wang et al., Science 316, 1194 (2007).
17. S. Matsuoka et al., Science 316, 1160 (2007).
18. R. A. DiTullio Jr. et al., Nat. Cell Biol. 4, 998 (2002).
19. L. B. Schultz, N. H. Chehab, A. Malikzay, T. D. Halazonetis, J. Cell Biol. 151, 1381 (2000).
20. V. Plans, M. Guerra-Rebollo, T. M. Thomson, Oncogene, in press. Published online 3 September 2007 (10.1038/sj.onc.1210782).
21. R. Kittler, A. K. Heninger, K. Franke, B. Habermann, F. Buchholz, Nat. Methods 2, 779 (2005).
22. D. Durocher, J. Henckel, A. R. Fersht, S. P. Jackson, Mol. Cell 4, 387 (1999).
23. K. Ito et al., Eur. J. Biochem. 268, 2725 (2001).
24. I. Hickson et al., Cancer Res. 64, 9152 (2004).
25. J. Bothos, M. K. Summers, M. Venere, D. M. Scolnick, T. D. Halazonetis, Oncogene 22, 7101 (2003).
26. G. Y. Zhao et al., Mol. Cell 25, 663 (2007).
27. V. Plans et al., J. Cell. Biochem. 97, 572 (2006).
28. We thank members of the Durocher and Jackson laboratories for input on the manuscript and M. Vojvodic for experimental assistance. We also thank A. C. Gingras for the stable YFP-RNF8 line, KuDOS Pharmaceuticals for providing inhibitors and reagents, and Abcam for the MDC1 pT719 antibody. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) to D.D. and by funding from Cancer Research UK and the European Union (S.P.J.). N.K.K. is a CIHR postdoctoral fellow and an alumnus of the Excellence in Radiation Research for the 21st Century training program; F.D.S. holds a Terry-Fox studentship from the National Cancer Institute of Canada; S.N. is a Gail-Posluns Fellow and is supported by the Mitsubishi Pharma Research Foundation. D.D. is a Canada Research Chair (Tier II) in Proteomics, Functional Genomics, and Bioinformatics.